跳至主要内容
临床试验/NCT07324330
NCT07324330招募中不适用

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

University Hospital, Bonn1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2025年12月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
130
试验地点
1
主要终点
Cognitive Performance: Change in MCI in PD Level II Criteria

研究概览

简要总结

α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated REM sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.

The aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.

Eighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the DZNE Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, MRI and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https://clinicaltrials.gov/study/NCT06993142). We also foresee synthesizing selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-into one meta-analysis.

详细描述

α-Synucleinopathies are the second most common group of neurodegenerative diseases after Alzheimer's disease (AD). Their prevalence is expected to increase significantly, with more than 12 million people worldwide likely to be affected by 2040. Clinical manifestations include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). These diseases are characterized by neuronal inclusions of α-synuclein aggregates and Lewy bodies, which lead to premature aging of the brain. In addition to motor impairments, cognitive decline is a central element of non-motor symptoms, which not only occurs in DLB but also affects up to 80% of people with PD. Cognitive deficits can often occur in the early stages of the disease and significantly impair social functioning and quality of life. Despite their high prevalence, there are currently only a few therapeutic approaches for treating cognitive impairments in α-synucleinopathies. Therefore, easily accessible, early preventive interventions are crucial to counteract cognitive decline.

Isolated REM sleep behavior disorder (iRBD) is considered an early sign of α-synucleinopathy and can be reliably diagnosed using video polysomnography. Over 90% of individuals with iRBD develop either PD or DLB within 20 years of diagnosis, with an approximately equal distribution between the two entities. It is noteworthy that executive functions can often already be impaired in iRBD, which is associated with an increased risk of early conversion to PD or DLB. Thus, iRBD represents a phase of early neurodegeneration in which there is a high risk of cognitive decline. For this reason, individuals with iRBD are a particularly suitable target group for investigating the effects of lifestyle modifications that could slow the progression of the disease at an early stage.

Increasing physical activity could offer a promising way to slow the progression of neurodegenerative processes in the early stages of α-synucleinopathies. Since motor impairments are a central feature of PD and DLB, many affected individuals-even in the early stages of the disease-do not achieve the recommended level of physical activity. Studies on increasing physical activity have shown that physical training has positive effects on cerebrovascular function and cognitive performance, both in healthy aging and in various neurodegenerative diseases. For α-synucleinopathies in particular, there is evidence from animal models, observational studies, and clinical trials with up to six months of follow-up that physical activity may have disease-modifying effects. A recent meta-analysis in PD found that various interventions to increase physical activity have moderate effects on global cognition and even strong effects on executive functions. Therefore, promoting a more active lifestyle could be a promising strategy to positively influence the early course of α-synucleinopathies. Motivational mobile apps offer a novel way to increase physical activity, as they can be used completely independently, allowing for a high degree of scalability of the intervention.

Derivation of research questions

The following key questions will be addressed in the research project:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 50-80 years
  • Polysomnographically confirmed diagnosis of iRBD
  • Maximum of 120 minutes of sports/outdoor activities per day
  • Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
  • Basic smartphone skills
  • Sufficient knowledge of German (native language, C1 or C2)
  • Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
  • Consent to be informed of any additional findings
  • Healthy controls:
  • Age: 50-80 years
  • Maximum of 120 minutes of sports/outdoor activities per day
  • Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
  • Basic smartphone skills
  • Sufficient knowledge of German (native language, C1 or C2)
  • Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
  • Consent to be informed of any additional findings

排除标准

  • Relevant cardiovascular diseases
  • Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
  • Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
  • Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)
  • Healthy controls:
  • Relevant cardiovascular diseases
  • Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
  • Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
  • Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)
  • clinically diagnosed iRBD

结局指标

主要结局

Cognitive Performance: Change in MCI in PD Level II Criteria

时间窗: 12 months

Change in cognitive performance between the start of the study (baseline) and the time after the intervention (after 12 months of intervention), measured as the global mean of the results from a neuropsychological test battery according to MCI in PD Level II criteria by Litvan et al., 2012. Executive functions: * semantic word fluency * set-shifting abilities * inhibition * logical thinking Visual cognitive abilities: * spatial perception * working memory performance * processing speed * attention Memory functions: * verbal memory * visuospatial memory Linguistic abilities: * naming semantic * abstract thinking

Cognitive Performance: Change in mild cognitive impairment (MCI) in PD Level II Criteria

时间窗: 12 months

Change in cognitive performance between the start of the study (baseline) and the time after the intervention (after 12 months of intervention), measured as the global mean of the results from a neuropsychological test battery according to MCI in PD Level II criteria. Executive functions: * semantic word fluency * set-shifting abilities * inhibition * logical thinking Visual cognitive abilities: * spatial perception * working memory performance * processing speed * attention Memory functions: * verbal memory * visuospatial memory Linguistic abilities: * naming semantic * abstract thinking

次要结局

  • Motor functions: Change in MDS-UPDRS III(12 months)
  • Sleep behavior: Change in Polysomnography vlaues(12 months)
  • Change in blood-based markers for metabolism, neurodegeneration and inflammation.(12 months)
  • Cognitive performance: Change in scores in digital app(12 months)
  • Change in MRI-based markers of brain health(12 months)
  • Change in body composition(12 months)
  • Motor functions: Change Perdue-Pegboard-Test(12 months)
  • Motor functions: Change in digital testing outcomes(12 months)
  • Sleep behavior: Change in subjective sleep quality(12 months)
  • Motor functions: Change in Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III(12 months)
  • Sleep behavior: Change in Polysomnography (PSG) read-outs(12 months)
  • Change in blood-based markers for metabolism.(12 months)
  • Change in blood-based markers for neurodegeneration.(12 months)
  • Change in blood-based markers for inflammation.(12 months)
  • Cognitive performance: Change in performance in digital app(12 months)
  • Change in Quantitative MRI Measures of Brain Structure and Function(12 months)

研究者

发起方
University Hospital, Bonn
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Michael Sommerauer

Dr.

University Hospital, Bonn

研究点 (1)

Loading locations...

相似试验